InMed Pharmaceuticals

InMed Pharmaceuticals is a leader in the manufacturing and development of rare cannabinoids. InMed is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates and is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. InMed is also developing IntegraSyn™ to produce pharmaceutical-grade cannabinoids and recently announced a definitive agreement to acquire BayMedica, a leader in the commercialization and manufacture of rare cannabinoids.